DT-216P2 Shows Rapid Improvement in Friedreich Ataxia After Just 4 Weeks

Design Therapeutics’ DT-216P2 improved Friedreich ataxia symptoms in early trial, increased frataxin levels and was well tolerated with no serious side effects.